Susceptibility of clinical methicillin-resistant Staphylococci isolates to new antibiotics

Abstract

Background: The treatment of methicillin-resistant staphylococcal infections has been a growing problem both in and out of hospitals for the past 30 years. Therefore, there is a need for other antibiotics as an alternative to glycopeptides in the treatment of methicillin-resistant staphylococcal infections. This study investigated the in vitro susceptibility of 49 methicillin-resistant Staphylococcus aureus (MRSA) and 59 methicillin-resistant coagulase negative staphylococci (MRCNS) clinical isolates to daptomiycin, telithromycin, tigecyclin, quinupristin/dalfopristin, and linezolid. Methodology: The identification of the strains was made by conventional methods. Antibiotic susceptibility tests were performed according to CLSI. Methicillin resistance was determined by cefoxitin disk. Susceptibilities of the strains to daptomycin, quinupristin/dalfopristin, tigecycline, and vancomycin were performed using the E-test according to the recommendations of CLSI 2011 and the manufacturer. Results: Two strains of MRCNS were resistant, and one was teicoplanin intermediate. It was found that one (2%) strain of MRSA and two (3%) strains of MRCNS were resistant to tigecyclin. Telithromycin resistance was detected in 33% of MRSA strains and 37% of MRCNS strains. Inducible clindamycin resistance was found in nine (18.4%) strains of MRSA and eighteen (30.5%) strains of MRCNS. All strains were susceptible to daptomiycin, quinupristin/dalfopristin, and linezolid. Conclusions:Although it has recently been used, telithromycin has a high percentage of resistance; its use for methicillin-resistant staphylococcal strains, therefore, should be limited. Daptomycin and quinupristin/dalfopristin were found to be effective against MRSA and MRCNS strains and were concluded to be a good choice in the treatment of methicillin-resistant staphylococci.

Identification of tigecycline- and vancomycin-resistant Staphylococcus aureus strains among patients with urinary tract infection in Iran

“…Another study demonstrated that 2% of MRSA and 3% of methicillin-resistant coagulase-negative staphylococci were resistant to tigecycline [27]. A study in Iran reported a tigecycline-resistant MRSA strain for the first time in 2013 [28].…”

Presence of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA) in the oral cavity of pedodontics clinics patients

“…Günümüzde MRSA enfeksiyonlarının tedavisinde klinikte kullanımda olan vankomisin ve teikoplanin olmak üzere iki glikopeptid grubu antibiyotikler ve 2000'li yıllardan sonra kullanıma giren linezolid, daptomisin ve tigesiklin gibi antibiyotiklere karşı direnç dünyada ve ülkemizde nadir olarak bildirilmiştir. [23][24][25][26][27][28] Çalışmamızda bu antibiyotiklere karşı direnç gözlenmemiştir.…”

Metisiline Dirençli Staphylococcus aureus İzolatlarının Antibiyotik Direnci ve Azalmış Vankomisin Duyarlılığının Araştırılması: Çok Merkezli Bir Çalışma

“…Ülkemizde henüz kullanıma girmeyen fakat dirençli suşların bildirildiği yeni antibiyotiklerden biri de K/D'dir. Yapılan çalışmalarda Öksüz ve arkadaşları 14 Kullanıma giren yeni antibiyotiklere rağmen MRSA enfeksiyonla¬rında temel tedavi seçeneği glikopeptidlerdir. Glikopeptid direnci ilk kez 2002 yılında ortaya çıkmış olup, son yıllarda dünyanın değişik bölgelerinde giderek artan oranlarda VISA/hVISA izolatları rapor edilmektedir 16,17 .…”